Switch theme
Sign up to access all valuation multiples
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. The vast majority of the company's revenue is generated in Europe. The company also operates in the USA, Japan, Russia, and Rest of the world.
1999
2.4K+
LTM Revenue n/a
LTM EBITDA n/a
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wockhardt has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Wockhardt achieved revenue of $324M and an EBITDA of $10.9M.
Wockhardt expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wockhardt valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $307M | $324M | XXX | XXX | XXX |
| Gross Profit | $226M | $178M | XXX | XXX | XXX |
| Gross Margin | 73% | 55% | XXX | XXX | XXX |
| EBITDA | -$9.5M | $10.9M | XXX | XXX | XXX |
| EBITDA Margin | -3% | 3% | XXX | XXX | XXX |
| Net Profit | -$28.3M | -$64.9M | XXX | XXX | XXX |
| Net Margin | -9% | -20% | XXX | XXX | XXX |
| Net Debt | $173M | $209M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Wockhardt's stock price is INR 1319 (or $15).
Wockhardt has current market cap of INR 214B (or $2.5B), and EV of INR 235B (or $2.7B).
See Wockhardt trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Wockhardt has market cap of $2.5B and EV of $2.7B.
Wockhardt's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Wockhardt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Wockhardt and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.7B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpWockhardt's NTM/LTM revenue growth is n/a
Wockhardt's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Wockhardt's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Wockhardt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Wockhardt and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -215% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wockhardt acquired XXX companies to date.
Last acquisition by Wockhardt was XXXXXXXX, XXXXX XXXXX XXXXXX . Wockhardt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Wockhardt founded? | Wockhardt was founded in 1999. |
| Where is Wockhardt headquartered? | Wockhardt is headquartered in India. |
| How many employees does Wockhardt have? | As of today, Wockhardt has 2.4K+ employees. |
| Is Wockhardt publicy listed? | Yes, Wockhardt is a public company listed on BOM. |
| What is the stock symbol of Wockhardt? | Wockhardt trades under 532300 ticker. |
| When did Wockhardt go public? | Wockhardt went public in 2000. |
| Who are competitors of Wockhardt? | Similar companies to Wockhardt include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Wockhardt? | Wockhardt's current market cap is $2.5B |
| What is the current revenue growth of Wockhardt? | Wockhardt revenue growth between 2023 and 2024 was 5%. |
| Is Wockhardt profitable? | Yes, Wockhardt is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
